1. Home
  2. ADIL vs AIMD Comparison

ADIL vs AIMD Comparison

Compare ADIL & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adial Pharmaceuticals Inc

ADIL

Adial Pharmaceuticals Inc

N/A

Current Price

$4.18

Market Cap

10.2M

Sector

Health Care

ML Signal

N/A

Logo Ainos Inc.

AIMD

Ainos Inc.

N/A

Current Price

$0.82

Market Cap

10.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADIL
AIMD
Founded
2010
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2M
10.6M
IPO Year
2017
2008

Fundamental Metrics

Financial Performance
Metric
ADIL
AIMD
Price
$4.18
$0.82
Analyst Decision
Buy
Analyst Count
4
0
Target Price
★ $8.33
N/A
AVG Volume (30 Days)
31.6K
★ 99.3K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $124,157.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 498.95
52 Week Low
$0.13
$0.80
52 Week High
$9.53
$3.88

Technical Indicators

Market Signals
Indicator
ADIL
AIMD
Relative Strength Index (RSI) 48.37 19.02
Support Level $3.80 N/A
Resistance Level $4.94 $1.68
Average True Range (ATR) 0.36 0.10
MACD 0.10 -0.03
Stochastic Oscillator 65.00 6.84

Price Performance

Historical Comparison
ADIL
AIMD

About ADIL Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.

About AIMD Ainos Inc.

Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.

Share on Social Networks: